Larimar Therapeutics (LRMR) Notes Payables (2014 - 2020)

Larimar Therapeutics (LRMR) has reported Notes Payables for 7 consecutive years, with $7.3 million the latest figure, recorded in Q1 2020.

• For the quarter ending Q1 2020, Notes Payables changed 0.0% year-over-year to $7.3 million; the trailing twelve-month figure through Mar 2020 stood at $7.3 million (changed 0.0% YoY), and the FY2019 full-year result was $7.3 million, up 33.33% from the prior year.
• Notes Payables held at $7.3 million in Q1 2020 per LRMR's latest filing, from $7.3 million in the prior quarter.
• Across five years, Notes Payables topped out at $7.3 million in Q1 2019 and bottomed at $1.3 million in Q3 2017.
• Historically, Notes Payables has averaged $4.4 million across 5 years, with a median of $3.6 million in 2016.
• The sharpest annual moves came in 2017 and 2019: Notes Payables sank 59.35% in 2017, then soared 300.06% in 2019.
• Over 5 years, Notes Payables stood at $3.6 million in 2016, then slumped by 64.67% to $1.3 million in 2017, then jumped by 330.21% to $5.5 million in 2018, then jumped by 33.33% to $7.3 million in 2019, then changed by 0.0% to $7.3 million in 2020.
• According to Business Quant data, Notes Payables over the past three periods registered $7.3 million, $7.3 million, and $7.3 million for Q1 2020, Q4 2019, and Q3 2019 respectively.